Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

NCT07707778 · Enrolling by invitation

Last updated 2026-07-28

This clinical trial is testing whether the medication tirzepatide can affect biological aging and improve metabolism in adults living with HIV who have controlled viral levels.

Status Enrolling by invitation Only people invited by the researchers can join.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-06 · est. completion 2027-12

Where 1 site · Taiwan

What this study is testing ClinicalTrials.gov NCT07707778 ↗

Description as written by the study sponsor.

This study is a pilot, open-lable, two-arm study. The investigators will enroll virally suppressed people living with HIV and obesity to evaluate the effect of tirzepatide on epigenetic aging, assessed by DNA methylation-based clocks using peripheral blood. In parallel, imaging studies will be performed to assess changes in body composition and intrahepatic fat content.

Treatments tested

Tirzepatide Drug

Tirzepatide will be given to the study arm after 8 weeks of diet and nutrition services. Study arm will receive a total of 25 weeks of tirzepatide.

Main thing measured	Second generation epigenetic aging clock
Sponsor	National Taiwan University Clinical Trial Center
Conditions studied	Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease, Dyslipidaemia, Diabetes Mellitus, Obesity & Overweight, Metabolic Syndrome
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07707778 ↗